Artificial Intelligence: Atomic AI Closes $35M Series ‘A’ For RNA Drug Discovery

Atomic AI had previously raised a $7 million seed round.

Atomic AI, a biotechnology company, has developed a proprietary, AI-driven ‘Platform for AI-driven RNA Structure Exploration’ (PARSE). PARSE is a 3D RNA structure discovery engine that can vastly improve RNA structure prediction and develop a new generation of RNA-targeting medicines to tackle diseases that were previously untreatable. The company came out of stealth with a $35 million Series A round led by Playground Global, with participation from 8VC, Factory HQ, Greylock, NotBoring, AME Cloud Ventures, and renowned angel investors including GitHub ex-CEO Nat Friedman, Doug Mohr, Curai CEO Neal Khosla, and UC Berkeley professor and Arc Institute Co-founder Patrick Hsu. (Businesswire)

“To create effective and safer small molecules against undruggable diseases, there is a significant need to develop tools that can accurately predict 3D RNA structures,” said Raphael Townshend, Ph.D., Founder and CEO of Atomic AI. “Atomic AI is oriented at the cutting edge of AI, RNA, and structural biology. We are creating an entirely new field of drug discovery.” Dr. Raphael Townshend was recognized in Forbes’ 30 under 30 for Science in 2023.

Atomic AI’s technology can discover structured, ligandable RNA motifs at unprecedented speed and accuracy, a critical barrier to current approaches in small molecule drug discovery against RNA. Beyond RNA-targeted molecules, the integrated platform will also enable the design of RNA-based medicines and RNA tools.

“There are well-known RNA sequences that play a critical role in driving disease; however, current technologies lack the RNA-structure modeling capabilities necessary to create confidence in RNA-targeting drug discovery,” said Gene Yeo, Professor of Cellular and Molecular Medicine at the University of California San Diego (UCSD), an expert in RNA biology and member of Atomic AI’s advisory board. “Atomic has created a sophisticated and integrated AI engine that will transform the discovery and development of RNA-targeted medicines.”

Related Story:  Atomwise To Collaborate With Sanofi On AI-Powered Drug Discovery

Image Credit: Flickr

Free Industry News

Subscribe to our free newsletter for updates and news about alternatives investments.

  • This field is for validation purposes and should be left unchanged.


Latest Alternative Investment News
Artificial Intelligence: AMD Takes On Rivals In The AI Chip Sweepstakes
December 7, 2023     Artificial Intelligence, News

Chipmaker AMD (NASDAQ: AMD) has unveiled a range of innovative AI solutions spanning from data centers to personal computers. The AMD Instinct MI300 Series features data center AI accelerators, while…
Digital Assets: Robinhood Debuts Crypto Trading On Its App In The EU
December 7, 2023     Digital Assets, FinTech, News

Robinhood (NASDAQ: HOOD) has launched its Crypto app in the European Union (EU), allowing eligible customers to engage in crypto trading with the added incentive of earning Bitcoin rewards. Customers…
FinTech: Samsung Electronics Ties With Mastercard’s Wallet Express
December 7, 2023     FinTech, News

Samsung Electronics (KRX: 005930) and Mastercard (NYSE: MA) have partnered to launch the Wallet Express program, offering banks and card issuers a cost-effective way to expand digital wallet offerings. Through…
Venture Capital: Revaia, Europe’s Biggest Female-Led VC Firm, Racks Up $160M For Second Fund
December 7, 2023     ESG and Sustainability, News, Venture Capital

Revaia, Europe’s largest female-founded venture capital firm, has successfully raised €150 million ($160 million) for its second fund, Revaia Growth II. The funding was secured from sovereign wealth funds, family…